Circulating Metabolites as Potential Biomarkers for Neurological Disorders—Metabolites in Neurological Disorders

• Main Authors: Amanda Donatti, Amanda M. Canto, Alexandre B. Godoi, Douglas C. da Rosa, Iscia Lopes-Cendes
• Format: Article
• Language: English
• Published: MDPI AG 2020-09-01
• Series: Metabolites
• Subjects: amyotrophic lateral sclerosis; Alzheimer’s disease; epilepsy; multiple sclerosis; Parkinson’s disease; stroke
• Online Access: https://www.mdpi.com/2218-1989/10/10/389

There are, still, limitations to predicting the occurrence and prognosis of neurological disorders. Biomarkers are molecules that can change in different conditions, a feature that makes them potential tools to improve the diagnosis of disease, establish a prognosis, and monitor treatments. Metabolites can be used as biomarkers, and are small molecules derived from the metabolic process found in different biological media, such as tissue samples, cells, or biofluids. They can be identified using various strategies, targeted or untargeted experiments, and by different techniques, such as high-performance liquid chromatography, mass spectrometry, or nuclear magnetic resonance. In this review, we aim to discuss the current knowledge about metabolites as biomarkers for neurological disorders. We will present recent developments that show the need and the feasibility of identifying such biomarkers in different neurological disorders, as well as discuss relevant research findings in the field of metabolomics that are helping to unravel the mechanisms underlying neurological disorders. Although several relevant results have been reported in metabolomic studies in patients with neurological diseases, there is still a long way to go for the clinical use of metabolites as potential biomarkers in these disorders, and more research in the field is needed.